Nigeria is advancing its healthcare research capabilities with the creation of a biobank housing over 400,000 biological samples, a project led by the Nigerian Institute of Medical Research (NIMR). The biobank, built through years of clinical studies and partnerships, aims to produce health data specific to Nigeria's population, reducing reliance on foreign datasets that often fail to reflect local genetic and environmental conditions. John Oladapo Obafunwa, director-general of NIMR, stated the biobank enables Nigeria to study diseases based on its own people, particularly as the country battles both persistent infections like malaria and rising cases of cancer and diabetes. The repository includes samples linked to infectious and non-communicable diseases, supporting faster diagnosis, better surveillance, and locally tailored treatments.
Despite its scale, the biobank's impact is constrained by weak infrastructure, poor data management, and a shortage of experts in bioinformatics and genome sequencing. Obafunwa acknowledged that without improved systems, the full value of the samples cannot be unlocked. Nigeria still sends samples abroad for advanced analysis, increasing costs and delays. NIMR is pursuing international collaborations, including a recent meeting with Chinese scientists in Lagos, to secure technology transfer and training. The institute's role in the COVID-19 response revealed both its strategic importance and systemic weaknesses, including inadequate laboratory capacity and funding delays.
The biobank's existence exposes a paradox: Nigeria can collect 400,000 samples but still cannot process them at scale. John Oladapo Obafunwa's admission about lacking the expertise and infrastructure to analyze this data reveals that collection is not capability. For Nigerians, this means health decisions will continue to lag behind even as local data accumulates. Without urgent investment in lab systems and training, the biobank risks becoming a shelf of unused potential.
